Daflon

ApprovedSmall molecule

UUniversitaire Ziekenhuizen KU Leuven

Daflon is one of 38 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

Polycystic Ovary SyndromeApproved

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Glucophage

Boehringer Ingelheim

Phase 3

2 2

Daflon

UUniversitaire Ziekenhuizen KU Leuven

Approved

1 3

Sequential Lenvatinib

SSun Yat-sen University

Phase 3

1 4

Clomid

Ferring

Preclinical

13 5

Oral Contraceptive Pill

WWayne State University

Phase 3

1 6

Precose

Bayer

Preclinical

2 7

Proglycem

Teva

Preclinical

1 8

Clomid

EMD Serono

Preclinical

3 9

Cetrotide

EMD Serono

Preclinical

3 10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Helicobacter Pylori Infection

NCT06546111

Q2 2027

Not yet recruiting

Treatment

NCT06318988

Clinical

Trials by Indication[1]

Chronic Venous Insufficiency2 trials

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

Unknown status·LLaboratório Teuto Brasileiro S/A·Phase 3·NCT01477281·82 enrolled

Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)

Unknown status·AAzidus Brasil·Phase 3·NCT01110512·140 enrolled

Treatment2 trials

Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Completed·IInterregional Clinical Diagnostic Center, Russia··NCT04512443·83 enrolled

Outcomes of Different Treatment Options in Chronic Venous Disease

Not yet recruiting·UUniversitaire Ziekenhuizen KU Leuven··NCT06318988·2,000 enrolled

Polycystic Ovary Syndrome1 trial

Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome

Unknown status·—·Phase 4·NCT06083935·120 enrolled

Helicobacter Pylori Infection1 trial

Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection

Recruiting·SSadat City University·Phase 1/2·NCT06546111·46 enrolled

Efficacy1 trial

Efficacy and Tolerability of the Use of Varicell Compared With Daflon

Unknown status·VVidfarma Indústria de Medicamentos Ltda.·Phase 3·NCT01321619·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Daflon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daflon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daflon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Daflon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Chronic Venous Insufficiency2 trials

Treatment2 trials

Polycystic Ovary Syndrome1 trial

Helicobacter Pylori Infection1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News